Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010897 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL22010508 | 0.77 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL5940036 | 0.76 | WNT1 (0.32) | P2RY14CCNT1CDK9 | |
| SCHEMBL5940045 | 0.76 | WNT1 (0.32) | P2RY14CCNT1CDK9 | |
| SCHEMBL5940042 | 0.76 | WNT1 (0.32) | P2RY14CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL5938664 | 0.75 | WNT1 (0.32) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL5938681 | 0.75 | WNT1 (0.32) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL5938674 | 0.75 | WNT1 (0.32) | CCNT1CDK9 | |
| SCHEMBL22010484 | 0.75 | MEN1 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL22010770 | 0.73 | HRH3 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | CHRNB2 4851/4885CHRNB4 4842/4885CHRNA3 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.